MORE VIDEOS
Explore more

Breast Cancer - Inflammatory

Drug Targeting for Inflammatory Breast Cancer
Drug Targeting for Inflammatory Breast Cancer administrator 2 Views • 2 years ago

Presented At:
Cancer Research & Oncology 2018

Presented By:
Kevin Williams, PhD - Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University

Speaker Biography:
Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents.

Webinar:
Drug Targeting for Inflammatory Breast Cancer

Webinar Abstract:
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype accounting for ~15% of all breast cancer deaths. IBC is characterized by Stage III or IV at diagnosis, no solid tumor, typically not detected by mammogram and rapid progression from onset of disease. The incidence of IBC is higher in younger patients and in women of African descent. There are limited treatment options for IBC. Targeted therapy with drugs that target HER1/2 (if the cancer is HER2-positive) e.g. the HER1/2 tyrosine kinase inhibitor lapatinib are one of the few treatment options but drug resistance is observed in the clinic. In the first project, we characterized a novel isogenic-derived progression model of lapatinib drug resistance and re-sensitization using the IBC cell line SUM149. In this study, lapatinib-resistant rSUM149 cells showed cross-resistance to a number of the drugs previously shown to act on the parental cells. The rSUM149 cells had increased levels of anti-apoptotic proteins, increased antioxidant expression, and decreased ability to accumulate reactive oxygen species (ROS), all of which lead to inhibition of drug-induced apoptosis. These results strengthen the need for novel strategies to modulate cellular redox to overcome drug resistance in IBC. In the second project, a major effort of our lab is to identify novel modulators of the hedgehog pathway in breast cancer. Dysregulation of the developmental Hedgehog (Hh) pathway is observed in many cancers with activation of the downstream Hh pathway effector GLI1 being linked to tumorigenesis and invasiveness in breast cancer including IBC. We have profiled a collection of GLI-directed small molecule antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of IBC, with a subset including the direct GLI1 binder GANT61 demonstrating activity in vivo. Further, we have also shown that GLI1 is directly phosphorylated by the kinase DYRK1A at a site within its putative nuclear localization sequence suggesting a possible mechanistic role in modulating its function. Utilizing the BRITE Institute’s capabilities in high-throughput screening we have identified novel and potent DYRK1A inhibitors that are being assessed for cellular and in vivo efficacy.

Learning Objectives:
1. Understand some of the new and novel approaches to targeting inflammatory breast cancer
2. Understand why there are limited treatment options for IBC

Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtu....al-event/cancer-rese
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtu....al-event/cancer-rese
3. Click Here to get your PACE (Expiration date – October 11, 2020 10:30 AM)– https://www.labroots.com/credi....t/pace-credits/3117/

LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc

Inflammatory Breast Cancer Patient Advocacy | 2023 Inflammatory Breast Cancer Program Patient Forum
Inflammatory Breast Cancer Patient Advocacy | 2023 Inflammatory Breast Cancer Program Patient Forum administrator 2 Views • 2 years ago

Patient advocates Trish Vickery and Terry Arnold discuss the role of patient advocates in advancing research and treatment for inflammatory breast cancer at the 6th Annual IBC Program Patient Forum in April 2023.

For more information about the IBC Program, visit https://www.dana-farber.org/in....flammatory-breast-ca

Inflammatory Breast Cancer - Principles of Management
Inflammatory Breast Cancer - Principles of Management administrator 2 Views • 2 years ago

The video explains essential points for inflammatory breast cancer
1- Sequence of Rx: chemotherapy then Modified Radicle Mastectomy and then Radiation. Hormonal Rx if needed.
2- Stage patients with advanced breast cancer.NCCN discourages staging in patients with early breast cancer.
3- No Sentinal Node; level 1/2 lymph node dissection is recommended.
4- No role of Breast conservative therapy
5-Delayed reconstruction
#absite #generalsurgertboards
CVS Specialty patient Ellen Dugan battles Inflammatory Breast Cancer
CVS Specialty patient Ellen Dugan battles Inflammatory Breast Cancer administrator 2 Views • 2 years ago

Living with Inflammatory Breast Cancer is no easy task. See how CVS Specialty patient Ellen Dugan not only faces, but continuously overcomes her challenges with the aid of friends and family.
Inflammatory Breast Cancer-Dr Geeta Kadayaprath
Inflammatory Breast Cancer-Dr Geeta Kadayaprath administrator 3 Views • 2 years ago

Dr Geeta Kadayaprath is Director,Breast Surgical Oncology,Max Hospital,Delhi
Inflammatory Breast Cancer -- The Biology
Inflammatory Breast Cancer -- The Biology administrator 3 Views • 2 years ago

Dr. Fredika Roberston , Professor and Director of Translational research at MD Anderson Cancer center, talks about the current research and tools that have helped her lab in understanding the progression of the disease.
What is Inflammatory Breast Cancer? | Ginny Mason
What is Inflammatory Breast Cancer? | Ginny Mason administrator 3 Views • 2 years ago

Ginny Mason, BSN, RN, is the Executive Director of the Inflammatory Breast Cancer Research Foundation (ibcRF), a member of the Alliance and grass-roots organization dedicated to improving the lives of those touched by inflammatory breast cancer (IBC) through the power of action and advocacy. This is done by fostering innovative IBC research, educating stakeholders, and advocating for both patients and survivors. Ginny has served in a number of research advocacy positions in her lifetime and continues to serve on advisory boards and as a Komen Advocate in Science. Ginny helped develop and implement the IBC Research Foundation BioBank and Clinical Data Base project in 2005. Ginny continues to manage patient enrollment, working with researchers and the Medical Advisory Board. She has spent close to 20 years since her diagnosis using her voice to advocate for breast cancer and metastatic breast cancer patients.

Inflammatory breast cancer (IBC) is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or inflamed. IBC is more difficult to diagnose than other types of breast cancer, and there is a lack of understanding of the disease… even among the medical community. Only increased awareness and education, and more research—including participation in clinical trials—can help improve outcomes and quality of life for IBC patients.

This video is part of the Metastatic Breast Cancer Alliance's Here All Year campaign. Breast Cancer Awareness Month is just October, but we're Here All Year.

The Metastatic Breast Cancer Alliance strives to ensure that all metastatic breast cancer patients and their caregivers know how to and are able to access the care and services they need from a responsive and well-informed healthcare system. We are doing that by working to build understanding of Metastatic Breast Cancer and how it differs from early stage breast cancer among those diagnosed—as well as their families, health care providers, researchers, and health policy makers and influencers.

Each month, our Here All Year campaign explores a new topic around metastatic breast cancer—from myth and stigma busters, to new research and strategies for improving outcomes. Want to help make a difference for people living with MBC, all year long? Dig deeper into the research, explore the available resources and share them on your social and email channels.
Inflammatory Breast Cancer Patient Forum 2019, Expert Q&A Panel | Dana-Farber Cancer Institute
Inflammatory Breast Cancer Patient Forum 2019, Expert Q&A Panel | Dana-Farber Cancer Institute administrator 4 Views • 2 years ago

At the third annual Inflammatory Breast Cancer Patient Forum, inflammatory breast cancer clinicians and patient advocates answered questions from the participants. The panelists included Jean Landry, MSN, NP; Faina Nakhlis, MD; Sharon Bober, PhD; Julie Salinger, MSW, LICSW; Huma Rana, MD; Julia S. Wong, MD; Heather Jacene, MD; and Trish Vickery.

To learn more, visit www.dana-farber.org/inflammato....ry-breast-cancer-pro

Facing Anxiety with IBC Diagnosis and Beyond | 2023 Inflammatory Breast Cancer Program Patient Forum
Facing Anxiety with IBC Diagnosis and Beyond | 2023 Inflammatory Breast Cancer Program Patient Forum administrator 2 Views • 2 years ago

Julie Salinger, MSW, LICSW, an oncology social worker in the Inflammatory Breast Cancer (IBC) Program, shares information about coping with anxiety around a diagnosis of IBC and beyond at the 6th Annual IBC Program Patient Forum in April 2023.

For more information about the IBC Program, visit https://www.dana-farber.org/in....flammatory-breast-ca

How I Found Out I had LUNG Cancer During My Breast Cancer Treatment | Christine's Story
How I Found Out I had LUNG Cancer During My Breast Cancer Treatment | Christine's Story administrator 0 Views • 2 years ago

Watch Christine's Part 1: https://youtu.be/IdlR7OaaqVY

Christine Elliott was diagnosed with breast cancer at 31 and during treatment, she unexpectedly discovered she had stage 2A lung cancer, despite experiencing no symptoms. At first, doctors thought it was insignificant, but Christine's persistence and intuition compelled her to advocate for further investigation. She insisted on a biopsy, which revealed a lung tumor.

In this conversation, Christine voices how she advocated for her health, what lead to her second cancer and her message to always listen to your body.

Full story & transcript → https://www.thepatientstory.co....m/patient-stories/lu

Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story

#thepatientstory #cancerstories #lungcancer #lungcancerawareness #bcsm #triplepositivebreastcancer #cancervlog #breastcancer #breastcancerawareness #cancersurvivor #cancerawareness #beatcancer #cancertreatment #cancerjourney

Showing 1 out of 2